Pure Global
NCT06385197

Improving the Effect of Multiple Sclerosis Drugs by Chronobiology

Improving the Effect of Dimethyl Fumarate and Diroximel Fumarate (DRF) for Patients With Multiple Sclerosis by Chronobiology
Hadassah Medical Organization·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Drug/Device/Intervention
App randomizing dosing regimen
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Hadassah Medical Organization
Location
Jerusalem, Israel
Timeline & enrollment
Phase
N/A
Start date
May 08, 2022
End date
Jun 02, 2023
Enrollment
8 participants
Primary outcome

safety assessment,assessment of AE,assessment of AE

Summary

A trial for evaluating the ability to improve the effect of dimethyl fumarate in patients
 with Multiple Sclerosis (MS) by chronobiology A controlled-randomization dosing regimen
 administered to patients with MS and provided by a designated app. The treatment limitations
 of time interval is pre-defined according to approved therapeutic windows.

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06385197
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06385197 through Pure Global AI's free database. This phase not specified trial is sponsored by Hadassah Medical Organization and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.